Clinical trials
PSMA Positive Tumors or Tumor Tissues clinical trials
Below are recruiting psma positive tumors or tumor tissues clinical trials, each written for real people, not researchers. We’re tracking 1,296 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05620693Recruiting
Cell therapy study for NY-ESO-1–positive soft tissue cancer
This trial tests an engineered immune cell treatment (NY-ESO-1 TCR-T) for people with advanced soft tissue sarcoma that has returned or spread after standard treatment. It aims to treat cancer cells that show a specific marker (NY-ESO-1) in the tumor.
Shenzhen, GuangdongAges 18–70 - NCT05562024RecruitingPhase 1
Study drug for B7-H3 positive neuroblastoma after relapse
This Phase 1 study tests TAA06, an injection that targets a marker called B7-H3 on neuroblastoma tumor cells. It is for children who have neuroblastoma that has come back or did not respond to prior treatment, aiming to see whether the treatment is safe and can shrink tumors.
Jinan, ShandongAges 1 year+ - NCT05580796RecruitingEarly Phase 1
TCR-T cell therapy for HLA-A*02 positive solid tumors
This trial tests a personalized immune-cell treatment made from your own blood to target certain solid tumors. You may be eligible if your tumor has a specific protein pattern and you have tried standard treatments without success.
Beijing, Beijing MunicipalityAges 18–70 - NCT02275286RecruitingPhase 1/Phase 2
Trabectedin plus radiation for select soft tissue sarcomas
This trial studies whether adding a chemotherapy medicine called trabectedin to targeted radiation can help control certain soft tissue sarcomas. It focuses on specific cancer types and locations, aiming to shrink tumors while keeping radiation safe for nearby healthy organs.
BordeauxAges 18 years+ - NCT05961761RecruitingPhase 2
Testing propranolol plus pembrolizumab for advanced sarcoma
This Phase 2 trial tests whether combining propranolol (a blood-pressure/heart medicine) with pembrolizumab (an immune therapy) can help people with advanced angiosarcoma or undifferentiated pleomorphic sarcoma that has progressed after first-line chemotherapy. It aims to slow tumor growth and improve outcomes while also studying tumor markers from your biopsy tissue.
AarhusAges 18 years+ - NCT05839275RecruitingPhase 1/Phase 2
Radiation plus two medicines for high-risk soft tissue sarcoma
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05631886RecruitingPhase 1
Testing a cancer vaccine plus immune therapy for hard tumors
This early-phase trial tests whether combining a lab-made CAR-DC cancer vaccine with immune checkpoint medicines can shrink tumors that have specific genetic changes. It’s meant for people with advanced or returning (relapsed) solid tumors or certain lymphomas that match required tumor markers.
Beijing, Beijing MunicipalityAges 18–75 - NCT06062927Recruiting
Genes and scans predict response to immunotherapy and targeted therapy for advanced sarcoma
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
Beijing, Beijing MunicipalityAges 18–75 - NCT06156150Recruiting
B7-H4 protein in tumor vaccine for glioma
This study looks at a protein called B7-H4 to help create a potential vaccine for glioma (a type of brain tumor). It uses a small tissue sample taken during your surgery to check if the vaccine might work for you.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05650242RecruitingPhase 1
Study of BA1106 in people with advanced solid tumors
This study tests an experimental drug called BA1106 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe, tolerable, and whether it can help shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06203249Recruiting
Exploring lung health and immune system in a rare muscle disease
This trial looks at how the immune system and tiny organisms in the lungs may affect a rare condition called anti-MDA5 positive dermatomyositis, which can cause serious lung disease. It may help doctors understand why some patients get worse quickly and how to better treat them.
Beijing, Beijing MunicipalityAges 18–100 - NCT06225856RecruitingPhase 1
YY201 for advanced solid tumors and blood cancers
This trial tests a new drug, YY201, that targets a protein called STAT3, which may help certain advanced solid tumors and blood cancers. It is for people who have tried standard treatments without success.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06249256RecruitingEarly Phase 1
Fast CAR T cells for advanced solid tumors
This trial tests a new type of CAR-T cell therapy called Fast CAR T cells for people with advanced solid tumors. It is designed for patients whose tumors have certain markers (mesothelin and PD-L1) and who have not responded to or cannot tolerate standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06248697RecruitingEarly Phase 1
CAR-T cells targeting MSLN with PD-1/CTLA-4 blockers for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-T cells) that target a protein called MSLN on cancer cells, and also release a special antibody to block two other proteins (PD-1 and CTLA-4) that cancers use to hide from the immune system. It is for people with advanced solid tumors like non-small-cell lung cancer or mesothelioma who have not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04165590RecruitingPhase 1/Phase 2
Plasmodium immune treatment for advanced solid tumors
This Phase 1/2 study tests an immune treatment made from Plasmodium (a malaria-related organism) in people with advanced solid cancers. It aims to see how well the treatment can control tumors and is primarily focused on early safety and whether it shows signs of benefit.
Kunming, YunnanAges 18–70 - NCT06101082RecruitingPhase 1
Testing anti-HER2-CAR-T cells for advanced solid tumors
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
Shenyang, LiaoningAges 18–70 - NCT06223256RecruitingPhase 1
NBL-028 for advanced solid tumors with CLDN6
This trial tests a new drug called NBL-028 in people with advanced solid tumors that have a specific protein (CLDN6). It is for those who have already tried standard treatments. The goal is to see how safe and effective the drug is.
Shijiazhuang, HebeiAges 18 years+ - NCT05877924RecruitingPhase 1
Early-phase study of an injected cancer treatment for advanced tumors
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
Guanzhou, GuangdongAges 18 years+ - NCT06342336RecruitingPhase 1
HS-IT101 injection for advanced solid tumors
This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.
Beijing, Beijing MunicipalityAges 3 weeks–2 months - NCT05579275RecruitingEarly Phase 1
Study JCXH-212 to treat advanced solid tumors safely
This early trial tests whether JCXH-212 alone, or with toripalimab (an immunotherapy drug), is safe and tolerable in people with advanced solid cancers. It also looks at whether treatment can help by targeting tumor “neoantigens” found in your tumor tissue.
Beijing, Beijing MunicipalityAges 18–75 - NCT04444869RecruitingPhase 2
Lower-dose radiation with chemotherapy for low-risk HPV throat cancer
This trial tests whether a less intense (lower-dose) radiation plan, combined with chemotherapy, can control HPV-positive oropharyngeal (throat) cancer with fewer side effects. It targets people considered “low-risk” based on tumor size and lymph node involvement.
Columbia, MissouriAges 18 years+ - NCT07819136RecruitingPhase 1/Phase 2
REC-7735 for people with advanced solid tumors
This study tests a new drug called REC-7735 for people with solid tumors that have a specific genetic change (PIK3CA H1047R). The drug targets this change to try to stop the cancer from growing.
Grand Rapids, MichiganAges 18 years+ - NCT07822919RecruitingPhase 1
Study of AWT020 for advanced solid tumors
This trial tests an investigational drug called AWT020 for people with advanced solid tumors that have grown after standard treatment. The goal is to see if AWT020 can help shrink or control the cancer, and it might be an option for you if other treatments haven't worked or aren't suitable.
Plantation, FloridaAges 18 years+ - NCT07824934RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug, HEC-921, given alone or with other cancer treatments for people with advanced solid tumors. It may be an option for those who have tried standard treatments or who have a specific marker on their tumor.
ShanghaiAges 18 years+
Hear when a new PSMA Positive Tumors or Tumor Tissues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma positive tumors or tumor tissues?
- Yes. Clin2 currently lists 1,296 recruiting psma positive tumors or tumor tissues studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma positive tumors or tumor tissues trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma positive tumors or tumor tissues trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.